By Paige.AILearning Objectives
- Understand digital pathology AI and Paige's regulatory leadership in the category
- Identify Paige Prostate, Paige PanCancer Detect, and clinical performance data
- Evaluate when Paige fits a pathology lab vs PathAI or in-house development
What Is Paige.AI?
Paige.AI is the digital pathology AI platform — applying deep learning to whole-slide pathology images for cancer detection. The company holds the first-ever FDA de novo marketing authorization for an AI-based pathology product (Paige Prostate) — a regulatory landmark that established the FDA framework for AI in clinical pathology.
Clinical performance data: pathologists using Paige Prostate increased sensitivity from 89.5% to 96.8% on prostate cancer detection, with a 70% reduction in false negatives and 24% reduction in false positives. Beyond Prostate, Paige received FDA Breakthrough Device Designation for Paige PanCancer Detect — an AI-assisted diagnostic application for detecting cancer from multiple tissues and organs (currently research use only, not yet approved for diagnostic use).
💡Key Concept
Why digital pathology AI matters: Pathology — the analysis of tissue samples — has been one of the slower medical specialties to adopt AI. Each whole-slide pathology image is gigabytes of data with subtle morphological features that require expert interpretation. AI assistance helps pathologists work faster and more accurately, which matters because pathologist shortages and increasing biopsy volume mean diagnoses are increasingly delayed. Paige's clinical performance data (89.5% → 96.8% sensitivity) demonstrates AI assistance produces measurable diagnostic improvement, not just speed gains.
✅Tip
Visit Paige.AI: paige.ai — sold to academic medical centers, pathology labs, and pharmaceutical companies
Status & Pricing
Paige.AI is sold to pathology labs and pharmaceutical companies. Custom-quote enterprise pricing.
- First-ever FDA de novo AI pathology approval
- Prostate cancer detection on whole-slide images
- Clinical use approved
- FDA Breakthrough Device Designation
- Multi-tissue cancer detection
- Not yet approved for clinical diagnosis
- Drug discovery + clinical trial support
- Tissue-based biomarker analysis
- Pharmaceutical industry deployments
- Memorial Sloan Kettering and others
- Research + clinical deployments
- Tier 1 academic adoption
- Cloud + on-premises options
- HIPAA-compliant infrastructure
- Required for AI inference
Pricing varies by deployment scale, slide volume, and integration depth.
Core Capabilities
Paige Prostate (FDA De Novo Approved)
The flagship product. First-ever FDA de novo marketing authorization for an AI-based pathology product. Used for prostate cancer detection on whole-slide images (digitized biopsy slides).
Clinical performance:
- Sensitivity: 89.5% → 96.8% (pathologists with vs without Paige Prostate)
- 70% reduction in false negative diagnoses
- 24% reduction in false positive diagnoses
These are clinically meaningful improvements — false negatives in prostate cancer can delay treatment for aggressive cancers; false positives create unnecessary anxiety and invasive follow-up procedures.
Paige PanCancer Detect (FDA Breakthrough)
A more ambitious product. FDA Breakthrough Device designation for an AI application that detects cancer across multiple tissues and organs from different anatomic sites — including both common cancers and rare variants. The first designation of its kind for an AI-enabled tool with this breadth.
Currently in experimental stage — used for research purposes only, not yet approved for diagnosing patients clinically.
Whole-Slide Image Analysis
Paige operates on whole-slide pathology images — gigabyte-scale digital scans of tissue slides. Required infrastructure:
- Slide scanners (e.g., Leica Aperio, Hamamatsu) at the pathology lab
- Cloud or on-premises image storage
- Paige's AI inference running on the digital slides
- Integration with the pathology LIS (laboratory information system)
Memorial Sloan Kettering Heritage
Paige's founding scientific work was conducted at Memorial Sloan Kettering Cancer Center — one of the world's leading cancer research institutions. The Sloan Kettering link gave Paige access to vast pathology training datasets and clinical-validation infrastructure.
Pharmaceutical Partnerships
Beyond clinical pathology, Paige works with pharmaceutical companies for:
- Tissue-based biomarker analysis in clinical trials
- Patient stratification for targeted therapy development
- Drug discovery support through tissue-AI insights
This pharma revenue stream complements clinical pathology revenue.
Academic Medical Center Adoption
Paige is deployed at major academic medical centers — Memorial Sloan Kettering, leading European and Asian cancer centers — providing clinical validation and continuous improvement of the AI through diverse case exposure.
Strengths
- First-ever FDA de novo AI pathology approval (Paige Prostate) — regulatory leadership
- Strong clinical performance data: 89.5% → 96.8% sensitivity is meaningful
- 70% false negative reduction: Patient safety improvement
- FDA Breakthrough Device for Paige PanCancer Detect: Roadmap toward broad cancer detection
- Memorial Sloan Kettering heritage: Top-tier scientific foundation
- Pharmaceutical partnerships: Diversified revenue beyond clinical pathology
- Academic medical center adoption: Tier-1 deployment validation
Limitations & Considerations
- Whole-slide infrastructure required: Pathology labs need digital slide scanners ($100K+ capital) before deploying Paige
- Pathology workflow change: Adoption requires process changes for pathologists used to optical microscopy
- Paige PanCancer Detect not yet clinical: Research-only; clinical approval timeline uncertain
- Custom-quote pricing: Not transparent
- Specialty-specific scope: Currently best at prostate; broader cancers in development
- Competitor PathAI also strong: PathAI has strong pharma partnerships and broader cancer coverage
- Pathologist adoption variable: Some pathologists embrace AI assistance; others resist
Best Use Cases
| Use Case | Why Paige.AI Fits | Caveat |
|---|---|---|
| Prostate cancer pathology screening | FDA-cleared with strong clinical performance data | Requires digital slide scanner infrastructure |
| Academic medical center pathology | Memorial Sloan Kettering heritage + tier-1 deployments | Custom-quote pricing |
| Pharmaceutical clinical trial pathology | Pharma partnerships + biomarker analysis | Pharma-specific engagement model |
| Multi-cancer detection research | Paige PanCancer Detect for research use | Not yet approved for clinical diagnosis |
| Cancer center diagnostic improvement | False negative reduction is clinically meaningful | Pathologist workflow adoption required |
When to choose alternatives:
- Broader cancer detection coverage (research) → PathAI has strong pharma partnerships and broad cancer scope
- Hospital-wide imaging AI (radiology) → GE Healthcare Edison, Aidoc, Annalise for radiology AI
- General medical AI → not a substitute for radiology AI or LLM-based clinical AI
- Smaller pathology labs → cost of digital slide infrastructure may not justify
- Specific cancer types Paige doesn't yet cover → in-house algorithm development or other vendors
Key Takeaways
- Paige.AI is the digital pathology AI platform — first-ever FDA de novo approval for an AI-based pathology product with Paige Prostate (prostate cancer detection)
- Clinical performance: pathologists using Paige Prostate increased sensitivity from 89.5 to 96.8 percent, with 70 percent reduction in false negatives and 24 percent reduction in false positives
- Paige PanCancer Detect received FDA Breakthrough Device Designation for multi-tissue cancer detection — currently research use only, not yet approved for clinical diagnosis
- Memorial Sloan Kettering heritage; deployed at major academic medical centers; pharmaceutical partnerships provide diversified revenue
- Best fit for prostate cancer pathology screening at academic medical centers and large cancer-focused pathology labs; for broader cancer coverage in research, PathAI offers complementary capabilities
